Items in red are considered top priority.

A

Acid/Alkaline Myth, Article #3, p.45-46; June 2008 Newsletter, p. 14; June 2007 Newsletter, p. 13-14

Almonds and Almond Milk, Article #3, p. 27

Amino Acids, March 2010 Newsletter, p. 11-15, August 2010 Newsletter, p. 18-19

Angiogenesis

• Angiogenesis and ellagic acid, November 2010 Newsletter, p.9, September 2010 Newsletter, p. 8-9
• Web link to video of Dr. William Li discussing the importance of using natural strategies to block angiogenesis and tumor development, November 2010 Newsletter, p. 9

Anti-CD20 Monoclonal Antibodies (mAbs), January 2008 Newsletter, p. 16-17; December 2004 Newsletter, p. 6-7

A.P. John Clinic, March 2010 Newsletter, p.13

Apples, Article #3, p.36-37; September 2011 Newsletter, p.22

Armstrong, Lance, July 2005 Newsletter, p. 11-12

Avocado, Article #3, p. 39; October 2007 Newsletter, p. 12-13; June 2007 Newsletter, p. 4-5

Astaxanthin, Article #3, p.29; July 2011 Newsletter, p. 12-13, June 2011 Newsletter, p.22

_________________________________________

B

Bendamustine (Treanda)

• General information,  Article #6, p.7;  May 2006 Newsletter, p. 8-10, December 2004
• Comparative data for R-Bendamustine and R-CHOP as choice for initial treatment, August 2011 Newsletter, p. 11-14; February 2011 Newsletter, p. 14-17
• Results of 2009 NCI clinical trial, December 2009 Newsletter, "Bendamustine Better Than CHOP?", p. 15-17

Berries

• Berries as part of targeted natural strategies breakfast,  Article #3, p. 33-34; April 2011 Newsletter, p. 18-22 
•  NF Kappa B pathway,  October 2009. p. 16-17 
•  Blackberries and their effect on gene expression,  September 2008 Newsletter, p. 4
• Test tube study finds compounds found in berries kill cancer cells, May 2008 Newsletter, p. 11-12

Beta Glucans

• Supplementation during chemotherapy,  Article #8, p. 8-9

Bexxar

• General information, Article #6 , p.7;  June 2007 Newsletter, "Before, After and New Research", p.  11-13;  February 2005 Newsletter, "Bexxar in Balance", p. 4-6
•  As choice for initial treatment, #7, p. 14-15 
•  Research comparing  Zevalin and Bexxar,  July 2008 Newsletter, p. 13-14
• Research evaluating effectiveness, June 2010 Newsletter, p. 12-13

Biomarkers

• Biomarkers predicting overall survival time and transformation, March 2011 Newsletter, p. 10-12; September 2008 Newsletter, p. 5-6;  November 2006 Newsletter, p. 4-5

Bone marrow transplants (allogeneic), January 2005 Newsletter, p. 6-8

Bowel Concerns, June 2011 Newsletter, p. 13-18, August 2010 Newsletter, p. 13-17

Breakfast (jump start your TNS day), Article #3, p. 23-34

Brocolli and brocolli sprouts, Article #3, p.37-38; July 2011 Newsletter, p. 11-12, May 2011 Newsletter, p. 10-13

Brussels sprouts, July 2011 Newsletter, p. 11-12, May 2011 Newsletter, p. 10-13, November 2010 Newsletter, p. 8-9, Article #3, p. 37-38

Budwig diet, August 2006 Newsletter, p. 3-5

Bulky Tumors,  Article #7, p. 6-7

________________________________________________

C

CAL-101,  August 2011 Newsletter, p. 17-19

CD4 and CD8 Biomarkers-CD4/CD8 Ratio, March 2010 Newsletter, p. 3-4; February 2010 Newsletter, p. 3-6

Cell (genetic) signaling pathways and cancer, May 2011 Newsletter, p. 4-6, June 2008 Newsletter, p. 3-5

Celiac disease 

• February 2009 Newsletter, p. 11-12;  April 2008 Newsletter, p. 11-12
• Rice as substitute for wheat, Article #3, p. 56

Chemotherapy and Optimization Strategies

•  "When Chemotherapy Really Shines", September 2010 Newsletter, p. 3-6
• "Dietary and Lifestyle Strategies DURING Chemo", April 2010 Newsletter, p. 6-13
• "Dietary and Lifestyle Strategies AFTER Chemo", April 2010 Newsletter, p. 13-16
• Amercian Cancer Society 2011 research study on fish oil and chemotherapy showed dramatically increased response rates and overall survival time (compared with patients not taking fish oil) for NON-small cell lung cancer patients, April 2011 Newsletter, p. 15-17
• Fasting and chemotherapy, November 2010 Newsletter, p. 16
• When used to treat follicular lymphoma, Article #8, p. 2-3 
• Chemotherapy optimization strategies, Article #8, p. 3-13;  August 2007 Newsletter, p. 2-5
• Chemotherapy and Vitamin D, Article #8, p. 3-4
• Brisk walk on day of chemotherapy, Article #8,  p. 4
• Hyperthermia during chemotherapy, Article #8, p. 4-5
• Fish oil supplementation during chemotherapy, Article #8, p.6-8 
• Beta Glucan supplementation during chemotherapy, Article #8, p.8-9
• Vitamin supplementation during chemotherapy, Article #8, p. 9-10 
• Supplements to avoid during chemotherapy, Article #8, p. 10; August 2008 Newsletter, p. 15
• Suggested diet and lifestyle strategies during and following chemotherapy, Article #8, p.11-13; February 2009 Newsletter, p. 6-9;  October 2008 Newsletter, p. 14-17;  November 2006 Newsletter, p. 12-16
• What to do to get the best response during CHOP, Article #8, p. 14
• Ginger used to combat nausea during chemotherapy, June 2009 Newsletter, p. 18

Cheson, Dr. Bruce

• Update on maintenance rituximab, April 2011, June 2011 Newsletter, p. 6 
• Notes from Dr. Cheson Webcast of December 2008, January 2009 Newsletter, p. 8-9
• Web link to full text of "Hematology: The case against rituximab maintenance", by Dr. Bruce D. Cheson, November 2009 Newsletter, p. 11
• Web link to Dr. Cheson webcast  giving overview of follicular lymphoma, July 2007 Newsletter, p. 10

Chicken and turkey

• Foods to avoid,  Article #3, p.39

Chlorambucil

• General information, Article #6,  p.1-2.;  Article # 7, p.12
• Chlorambucil and stem cell transplants, April 2007 Newsletter, p. 6
• Research on highly effective outcomes for using chlorambucil in the treatment of mantle cell lymphoma, April 2011 Newsletter, p. 14-15, January 2011 Newsletter, p. 14-15
• Why so little use? (summary of clinical results prior to 2010), Article #7, p.17-22
• Excellent clinical results( best current info. and update), January 2010 Newsletter, p. 4-6
• Additional clinical results, September 2009 Newsletter, p. 11-13
• Updated protocol for "pulsing mode", August 2010 Newsletter, p. 20
• Chlorambucil, the non-sexy wonder drug (with extensive references),  November 2008 Newsletter,  p. 2-7
• Chlorambucil and rituximab, June 2007 Newsletter, p. 9-10

Chronic Hidden Infection, Article #3, p. 50-52; March 2008 Newsletter, p. 10-12;  November 2005 Newsletter, p.  4-7

Colostrum, Article #3, p. 55, December 2010 Newsletter, p. 18, April 2010 Newsletter, p.6

CoEnzyme Q-10, October 2010 Newsletter, p. 21, Article #8, p.10; March 2009 Newsletter, p. 10

Communication and Intimacy, Article #3, p. 61

CPOP, Article #6, p.9; January 2005 Newsletter, p. 8

CT Scans (see Scans)

Curcumin and Tumeric

• New recommendations for daily supplementation with curcumin and tumeric, January 2012 Newsletter, p. 20-21 
• Using curcumin and tumeric capsules in oil for daily supplementation, December 2011 Newsletter, p. 15-16
• Adding curcumin and tumeric to breakfast routine, Article #3, p. 31
• Deception in labeling and supplement buyer guidelines, June 2011 Newsletter, p. 23-24, March 2011 Newsletter, p. 21
• Downregulation of gene CXCR4 and curcumin, April 2007 Newsletter, p. 3
• Bioavailability of curcumin, November 2010 Newsletter, p. 16-17, October 2009 Newsletter, p. 20;  August 2008 Newsletter, p. 5-7; August 2007 Newsletter, p. 10-12
• Curcumin absorption and need to add to a fat, October 2006 Newsletter, p. 12-14 
• Green tea extract effectiveness  and curcumin, November 2007 Newsletter, p. 7-8;  July 2007 Newsletter, p. 5
• Curcumin and cancer -- research studies
• Possible effect on apoptosis (programmed cell death),  May 2009 Newsletter, p. 7-8
• Research on fNHL and curcumin, April 2007 Newsletter, p.3;  October 2006 Newsletter, p. 2-3;  August 2006 Newsletter, p.  6-7

·  Cure

•     Definition of cure compared with remission, April 2009 Newsletter, p. 6-8

 Cy  Cyclophospamide (Cy), August 2011 Newsletter, p. 14-16

[return to top ]

______________________________________

D

DCA, June 2011 Newsletter, p. 11-13, November 2010 Newsletter, p. 13, July 2010 Newsletter, p. 14: June 2010 Newsletter, p. 7-9, February 2007 Newsletter,  p. 2 , March 2007 Newsletter, p.3,  April 2007 Newsletter, p.2-3, September 2008 Newsletter, p.6-8

Depression, April 2010 Newsletter, p. 16-18

Devil's Claw, November 2009 Newsletter, p. 18

Diagnosis 

• General diagnosis information, Article #2, p. 6-10;  September 2005 Newsletter,  p. 2-3.
• "Obtaining the Correct Diagnosis", November 2010 Newsletter, p. 4-5
• Common sub-groups of patients at time of initial diagnosis, November 2010 Newsletter, p. 5-6 
• Lack of concurrence in diagnosis, Article #5,  p. 1;  September 2005 Newsletter,  p. 2-3. 
• Biopsies and diagnosis, Article #5, p. 1-2
• Composite histology, Article #5, p.1;  September 2008 Newsletter, p. 11-12;  October 2007 Newsletter, p. 7-8
• Discordant histology, Article #5, p.1-2;  September 2008 Newsletter, p. 11-12;  October 2007 Newsletter, p. 7-8
• Bone marrow biopsies, Article #5, p.2 
• FOXP3 biomarker as breakthrough in predicting survival and transformation, December 2009 Newsletter, p. 11-13
• CD4 and CD8 Biomarkers-CD4/CD8 Ratio as prognostic indicators for long term survival,  February 2010 Newsletter, p. 3-6

Dynamic Observation

• "Watch and Wait: Maintenance Rituximab ... Latest Expert Opinions", November 2011 Newsletter, p. 2-5
• As a viable option for pro-active, newly diagnosed patients,  May 2009 Newsletter, p. 14-15  
• Using lifestyle strategies during periods of dynamic observation, July 2008 Newsletter, p. 3-6 
• Comparison of dynamic observation as a choice for managing low-risk prostate cancer vs. low-risk fNHL, January 2011 Newsletter, p. 17-18
• Watch and wait: My friends don't understand, September 2006 Newsletter, p. 5-7 
• Watch and wait before and between treatments, January 2005 Newsletter, p. 4-6

_____________________________________________

E

Eggs,  Article #3, p. 27-28; February 2010 Newsletter, p.15, August 2010 Newsletter, p.19, September 2010 Newsletter, p. 19

Ellagic Acid

• Ellagic acid may block blood vessel formation in tumors, Article #3, p. 35-36
• Daily triple juice drink essential for therapeutic dose of ellagic acid, Article #3, p. 35-36
• In raspberries, pomegranate juice, walnuts and strawberries, Article #3, p. 35-36; July 2006 Newsletter, p. 5
• Ellagic acid's role in preventing angiogenesis, November 2010 Newsletter, p. 9, September 2010 Newsletter, p. 8-9
• Ellagic acid helps to regulate methylation process, February 2011 Newsletter, p. 5-6

Exercise

• Exercise as an important natural strategy, September 2011 Newsletter, p. 14-15;  Article #3, p. 46-48 
• Exercise -- 7 facts with more benefits than you think, January 2010 Newsletter, p. 6-9  
• Exercise for lymphoma patients -- trial results, October 2009 Newsletter, p. 11-12 
• Optimal time of day for exercise, November 2011 Newsletter, p. 17-18
• " Exercise: Providing Four Essential Benefits",  May 2010 Newsletter, p. 5-7
• Depression and exercise, Article #3,  p. 63
• Endorphins and exercise, March 2010 Newsletter, p. 17
• Evening exercise, March 2010 Newsletter, p. 17
• Research on cancer and exercise
• Beneficial results of aerobic exercise, October 2009 Newsletter, p. 11-13 
• High muscle strength and cancer mortality, July 2009 Newsletter, p. 16
• Various research studies on exercise and cancer, February 2008 Newsletter, p. 7-10
• Large study on physical activity and lymphoma, September 2007 Newsletter, p. 9-10
• Exercise and its effect on immunity, March 2005 Newsletter, p. 11-13

__________________________________________________

F

Faith, Article #3, p. 61-62

Flavonoids,  May 2009 Newsletter, p. 8-10;  June 2008 Newsletter, p. 6

Fish Oil

• American Cancer Society 2011 research study on fish oil and chemotherapy showed dramatically increased response rates and overall survival time (compared with patients not taking fish oil) for NON-small cell lung cancer patients, April 2011 Newsletter, p. 15-17 
• Supplementation during chemotherapy,  Article #8, p. 6-8

FLIPI score

• FLIPI and FLIPI 2, strengths and weaknesses as prognostic assessment tool, Article #2, p. 20-22
• Limitations of FLIPI for predicting survival,  December 2009 Newsletter, p.  11-13

Fludarabine

• Study shows R-Fludarabine regimen unsafe and not recommended for an upfront therapy for fNHL, November 2011 Newsletter, p. 11-13
•  "Major Caution re Fludarabine", November 2010 Newsletter, p. 12-13
• General information, Article #6, p. 5-6
• Fludarabine with CNOP, Article #6, p.9
• Combining with Rituximab (R-FND), Article #7, p. 13
• Possible impact on future stem cell transplants (SCTs), Article #7, p. 13

Follicular Lymphoma

• Defined as malignancy in evolution, Article #2, p. 10-12
• "The Seven Premises in Understanding and Managing fNHL", November 2010 Newsletter, p. 3-12 
• Web link to "Follicular Lymphoma Revisited"  (Dr. Saul Rosenberg reviews 25 years of fNHL research), March 2008 Newsletter,  p.6
• Probable causes and risk factors, Article #2, p. 12-16
•  Incidence rates, Article #2, p. 16-17 
• Explaining predicted survival and survival statistics, Article #2, p.17-22 
• The development and management of follicular lymphoma (a brief overview), October 2008 Newsletter, p. 2-7
• "What is an appropriate fNHL Checkup?",  February 2011 Newsletter, p. 17-19
• Dietary factors and fNHL incidence, September 2009 Newsletter, p. 8-10 
• Funding for fundamental research for fNHL, July 2008 Newsletter, p. 17-19;  October 2006 Newsletter, p. 8-12
• Stanford research on overall survival (OS) , Article #2, p. 17-18; December 2007 Newsletter, p. 5-7;  May 2005 Newsletter, p. 7-10
• Seasonal  variance in the incidence of fNHL, July 2007 Newsletter, p. 14-15
• Web link to Dr. Cheson webcast  presenting an overview of follicular lymphoma, July 2007 newsletter, p. 10 
• Follicular Lymphoma: An 80 year perspective, May 2007 Newsletter, p. 10-11

Foods to Avoid

• List of foods to avoid, Article #3, p. 39 
• Chicken and turkey, Article #3, p. 39

FOXP3 Biomarker 

• FOXP3 as breakthrough in predicting survival and transformation, December 2009 Newsletter, p. 11-13

Fungal Infections, May 2009 Newsletter, p. 10-12

____________________________________________________________

G

GEM-P, Article #6, p.9  

Genetic Research

• Gene EPHA7 an important biomarker for fNHL when switched off, December 2011 Newsletter, p. 8-9 
• Gene MLL2, connected to histone action, is discovered to be mutated and rendered inactive in 89% of newly diagnosed fNHL patients, August 2011 Newsletter, p. 22-24
• Genetic profiles as prognostic indicators for long-term survival, March 2006 Newsletter, p. 3-6
• Gene P53 and selenium supplementation, Article #3, p. 26; November 2008 Newsletter, p.9

Gerson therapy, April 2008 Newsletter, p. 14

Ginger

• Ginger drink,  Article #3, p.24;  June 2008 Newsletter, p. 7-9 
• Ginger used to combat nausea during chemotherapy,  June 2009 Newsletter, p. 18

Glutamine,  September 2009 Newsletter, p. 10-11

Glycolysis, June 2010 Newsletter, p. 3-6, July 2010 Newsletter, p. 13 

Grades of Follicular Lymphoma, Article #2, p. 4-6 

Grade 3  fNHL 

• "Grades 3A and 3B: Latest Essential Information", December 2010 Newsletter, p. 13-15
• General information: August 2008 Newsletter, p. 8-11; June 2008 Newsletter, p. 10-11;  November 2007 Newsletter, p. 18-19; August 2007 Newsletter, p. 8-9; October 2005 Newsletter, p. 5-6

Grass Fed Beef, Article #3, p. 39

Green Tea

• Precaution against green tea extract use during chemotherapy, February 2009 Newsletter, p. 12-13
• Green tea extract effectiveness and curcumin, November 2007 Newsletter, p. 7-8;  July 2007 Newsletter, p. 5 
• Green tea extract and B-cell malignancies, January 2006 Newsletter, p. 3-5

_____________________________________________________

H

H Pylori bacteria, February 2007 Newsletter, p. 7; January 2007 Newsletter, p. 8-10; October 2005 Newsletter, p. 6-8

Hemoglobin

• As a major indication of transformation, August 2008 Newsletter, p. 7-8
• Interpreting hemoglobin levels in blood tests, February 2010 Newsletter, p. 8-9

Herbicides and Pesticides

• As a risk factor for lymphoma, Article #3, p. 56-57; March 2010 Newsletter, p. 7-9
• Study linking pesticide exposure with lymphoma, July 2009 Newsletter, p. 10-11;  March 2005 Newsletter, p. 4-6

Histology (see Diagnosis)

Histone Deacetylase (HDAC) Inhibitors 

• Brocolli and brussell sprouts are natural HDAC inhibitors, May 2011 Newsletter, p. 11-13, Article #3, p. 37-38; December 2010 Newsletter, p.5-6, November 2010 Newsletter, p. 8-9
• Potential of HDAC inhibitors in helping to manage fNHL, July 2011 Newsletter, p. 6-10, October 2010 Newsletter, p. 6-7, August 2010 Newsletter, p. 6-9, June 2010 Newsletter, p. 15-17, August 2006 Newsletter, p. 7-9
• Sulforaphane as a natural HDAC inhibitor in foods, May 2011 Newsletter, p. 10-13, February 2011 Newsletter, p. 4-5

Hyperthermia/Heat Therapy/Hot Baths

• As a Targeted Natural Strategy, Article #3, p. 57-58 
• Hyperthermia  during chemotherapy, Article #8, p. 4-5
• Hyperthermia Clinical Trial results, 2009,  October 2009 Newsletter, p. 9-11

________________________________________________________

I

Immunity

• Fallacy of the "boosting the immune system" concept, November 2007 Newsletter, p.12-13
• Immunity, cancer and inflammation, January 2009 Newsletter, p. 5-7 

Immunoglobulins,

• Recommendation to get Ig levels (IgA, IgG, IgM) tested on a regular basis, January 2012 Newsletter, p. 15-17 
• Immunoglobulins and maintenance rituximab, November 2011 Newsletter, p. 2-5 
• Immunoglobulins normal range, Article #3, p.54
• Immunoglobulins and colostrum, Article #3, p.55, December 2010 Newsletter, p. 18 
• February 2010 Newsletter, p. 6-8
• Risks associated with below normal Immunoglobulins, April 2010 Newsletter, p. 3-6
• Details related to sub-normal vs. optimal levels of Immunoglobulins, May 2010 Newsletter, p. 15-16

Inflammation and cancer, January 2008 Newsletter, p. 14-16; October 2007 Newsletter, p. 3-6;  February 2007 Newsletter, p. 4-6

• Integrative medicine as distinct from "alternative medicine",  May 2009 Newsletter, p. 4-5.
• "Integrative Medicine ... Content, Context and Psychology", August 2010 Newsletter, p. 10-12 

   

_________________________________________

J

_________________________________________________

K

Kirschbaum, Dr. Mark

• New drug development based on epigenetic processes, July 2011 Newsletter, p.1-4, June 2011 Newsletter, p. 11, May 2011 Newsletter, p. 21-23

________________________________________________

L

LDH

•  LDH test, Article #3, p. 60-61 
•  Elevated LDH and transformation, Article #4, p.2

Lifestyle Strategies  (see also Targeted Natural Strategies)

• Updated dietary strategies, Article #3, p. 23-46
• Reseach studies demonstrate dramatically reduced risk of breast cancer in women practicing healthy diet and lifestyle strategies, January 2012 Newsletter, p. 21-23; April 2011 Newsletter, p. 11-12
• Epigenetics and lifestyle strategies, May 2011 Newsletter, p. 2-24, October 2008 Newsletter, p. 9-10; July 2008 Newsletter, p. 3-6
• Using lifestyle strategies during periods of dynamic observation, July 2008 Newsletter, p. 3-6.
• "The New Direction in Cancer Research ... We're Already on the Way", August 2010 Newsletter, p. 3-10

Long-Term Survival (also see Planning Horizon)

• "Our Four Groups of Members: Who They Are and What They Need", September 2011 Newsletter, p. 3-17 
• "The "How to" Details for Lengthening Your Life -- Getting into the Thrive Zone with Epigenetics", May 2011 Newsletter, p. 2-24 
•  "From Knowledge to Success... 9 Essential Steps in Managing fNHL", March 2011 Newsletter, p.  3-9
• "The Five Key Things That Got Me This Far",  January 2011 Newsletter, p. 3-9
• "Cracking the Code for Entering the Thrive Zone", December 2010 Newsletter, p. 4-6 
• "Strategic Requirements for the Thrive Zone", December 2010 Newsletter, p. 6-8
• "The Seven Premises in Understanding and Managing fNHL", November 2010 Newsletter, p. 3-12 
• Key factors influencing long-term survival,  August 2009 Newsletter, p. 3-9
• An overall strategy for managing fNHL for long-term success,  February 2009 Newsletter, p. 2-6
• Planning for transformation: Most important considerations,  Article #7, p.16;  January 2009 Newsletter, p. 3-4 
• " 40 Must Know Things Learned After 22 Years -- Especially Important for the Newly Diagnosed", July 2010 Newsletter, p. 4-10
• " Maintaining a Clinical Remission",  September 2010 Newsletter, p. 6-9
• Depression and long-term survival, July 2008 Newsletter, p. 11-12 
• "New Research in Forecasting Survival Time", March 2011 Newsletter, p. 10-12
• Personal characteristics of long-term survivors, February 2010 Newsletter, p. 11-12 
• Stanford research on overall survival (OS), Article #2, p. 17-18; December 2007 Newsletter, p. 5-7; May 2005 Newsletter, p. 7-10 
• Three phases in the long-term management of follicular lymphoma, November 2007 Newsletter, p. 3-6
• Significance of relapse in long-term management and survival, September 2007 Newsletter, p.  4-5
• Genetic profiling as a prognostic indicator for long-term survival, March 2006 Newsletter, p. 3-6

Lymphoma Map for USA (all Non-Hodgkin's lymphomas), July 2009 Newsletter, p. 10

Lymphoma Specialists

• Guidelines for establishing patient-specialist relationship, Article #3, p. 58-60; January 2006 Newsletter, p. 8-9 
• Web link to North America's top lymphoma specialists, Article #3, p. 58

________________________________________________

Macrophages, January 2006 Newsletter, p. 7-8

Magnesium, Article #3, p. 29

Maintenance Rituximab (see Rituximab)

Manuka honey, March 2009 Newsletter, p. 12-14

Meditation, June 2010 Newsletter, p. 13-15

Methylation, December 2010 Newsletter, p. 6-7, November 2010 Newsletter, p. 8, October 2010 Newsletter, p. 6-7 

Mercury Dental Fillings, September 2007 Newsletter, p. 13-14

Microenvironment

• Immune nodal microenvironment and long-term survival, Article #2, p.17-20, January 2010 Newsletter, p. 12-14; April 2008 Newsletter, p. 2-5
• Original, symbolic portrayal of "corralling" lymphoma  in nodal microenvironment, December 2009 Newsletter, p. 3-11 
• Epigenetics and nodal microenvironment, December 2011 Newsletter, p.7-8; March 2009 Newsletter, p. 2-4
• CD4 and CD6 biomarkers and nodal microenvironment, February 2010, p. 3-6

MIME, Article #6, p.9

Mitochondria

• Warburg effect (cancer as a metabolic disorder), Article #3, p. 25, November 2010 Newsletter, p. 10, June 2010 Newsletter, p.3-6
• Resveratrol and mitochondria, Article #3, p. 25; December 2010 Newsletter, p. 7-8, July 2010 Newsletter, p. 13-15

Monoclonal Antibodies, January 2006 Newsletter, p. 5-6

MRSA, February 2011 Newsletter, p. 11-12;  May 2010 Newsletter, p. 14-15

Multitudinous Crossfire

• February 2010 Newsletter, p.14-15
• Multitudinous crossfire and epigenetics, September 2010 Newsletter, p. 11-13

Music, Article #3, p.63, January 2010 Newsletter, p. 22; July 2006 Newsletter, p. 8-9

N

Nanotechnology

• Used in early detection of cancer, October 2009 Newsletter, p. 17

NF-Kappa B pathway

• Berries down-regulate NF Kappa B, October 2009 Newsletter, p. 16-17 
• Experimental drugs targeting NF Kappa B pathway, October 2009 Newsletter, p. 17-18
• NF-Kappa B pathway ,high sugar intake, and inflammation, February 2008 Newsletter, p. 7
• NF-Kappa B pathway and tocotrienols, January 2008 Newsletter, p. 17-18

Night Sweats, November 2010 Newsletter, p. 14-15

·  Nutrients (from foods), June 2005 Newsletter, p. 9-11

       Nutritional Genomics, February 2005 Newsletter, p. 7-10

________________________________________________________

O

Oranges, Article #3, p. 36

Organochlorines

• As a risk factor for lymphoma, Article #3, p. 57; October 2007 Newsletter, p. 8-9
• Risk factors associated with chlorinated water, April 2009 Newsletter, p. 8-9 
• Troclosan in soaps interacting with chlorinated water, June 2005 Newsletter, p. 11-13

Ornish, Dr. Dean

• "With Thanks, Respect and Hope", April 2011 Newsletter, p. 7 
• Breakthrough research on epigenetics and prostate cancer, June 2008 Newsletter, p. 3-6
• Need for fNHL research on lifestyle changes and epigenetics patterned on Ornish's prostate cancer research, March 2011 Newsletter, p. 18-20; September 2010 Newsletter, p. 11-13

Oxytocin,  Article #3, p.62

__________________________________________________________

P

PACE, Article #6, p.9

Paradigm Shift (in understanding and treating fNHL), April 2006 Newsletter, p. 5-9; December 2005 Newsletter, p. 5-7

Paraneoplastic Syndrome, Article #3, p.52

PCR (R-PCR), January 2009 Newsletter, p. 4-5.

PEP-C, April 2008 Newsletter, p. 9-10

Pesticides (see Herbicides and Pesticides)

PET scans

• Research on high frequency of false positive PET scans in regard to diagnosis of relapsed lymphoma, June 2011 Newsletter, p. 18-20 
• Risks of over-exposure to radiation, January 2010, p. 14-17
• Limitations of PET scans, September 2007 Newsletter, p. 5-7;  May 2005 Newsletter, p. 10

Planning Horizon (also see Long-Term Survival)

• "Our Four Groups of Members: Who They Are and What They Need", September 2011 Newsletter, p. 3-17 
• "From Knowledge to Success ... 9 Essential Steps in Managing fNHL", March 2011 Newsletter, p. 3-9 
• "The Five Key Things That Got Me This Far",  January 2011 Newsletter, p. 3-9 
• "Cracking the Code for Entering the Thrive Zone", December 2010 Newsletter, p. 4-6
• "Strategic Requirements for the Thrive Zone", December 2010 Newsletter, p. 6-8
• Factors to consider in planning for 20 ++ years of survival, February 2010 Newsletter, p. 2-6;  November 2009 Newsletter, p. 3-5;  November 2006 Newsletter, p. 5-9
• Planning for transformation: Most important considerations, Article #7, p.16;  January 2009 Newsletter, p. 3-4 
• An overall strategy for managing fNHL for long-term success,  February 2009 Newsletter, p. 2-6 
• "40 Must Know Things Learned After 22 Years -- Especially Important for the Newly Diagnosed", July 2010 Newsletter, p. 4-10
• " Maintaining a Clinical Remission", September 2010 Newsletter, p. 6-9
• Three phases in the long-term management of follicular lymphoma, November 2007 Newsletter, p. 3-6 
• Significance of relapse in long-term management and survival, September 2007 Newsletter, p. 4-5

Plastics, February 2010 Newsletter, p. 10-11; February 2008 Newsletter, p. 10-11

Phytochemicals

• Suppression of cell-signalling pathways, October 2006 Newsletter, p. 8-9;  December 2004 Newsletter, p. 9-10

Pomegranate Juice, Article #3, p. 35-36; July 2006 Newsletter, p. 5

Prednisone, March 2010 Newsletter, p. 17-18

Problematic Nodes, Article #7, p. 5-6

Progression-Free Survival, April 2009 Newsletter, p. 7-8

PubMed, May 2010 Newsletter, p. 18

Q

_____________________________________________________________

R

R-Bendamustine (see Bendamustine) 

R-CHOP

• Comparison of R-CHOP and R-Bendamustine when used as an initial treatment, August 2011 Newsletter, p. 11-14 
• General information, Article #6, p. 4-5
• Critical information on possible shortages of chemotherapy drugs used to treat transformation, December 2010 Newsletter, p. 15-16
• As treatment for transformation,  Article #4, p. 2-4 
• CHOP and the heart, April 2010 Newsletter, p. 21-23
• R-CHOP as a choice for initial therapy, Article #7, p.14.
• Comparative data for R-CHOP and Bendamustine as choice for initial therapy, February 2011 Newsletter, p. 14-17 
• Dose-dense R- CHOP, Article #7, p.15;  March 2005 Newsletter, p. 6-8
• Using Co-Enzyme Q-10 when receiving CHOP, October 2010 Newsletter, p.21, Article #8, p.9;  March 2009 Newsletter, p. 10 
•  R-CVP vs. R-CHOP with managerial implications, April 2009 Newsletter, p. 2-5
• Doxorubicin caution, January 2008 Newsletter, p. 18-19 
• ECG suggested before treatment with R-CHOP, February 2011 Newsletter, p. 19-20
• Increased potential of R-CHOP to markedly increase survival rates when reserved for probable event of transformation, August 2008 Newsletter, p. 7-8
• Valsartan to prevent chronic doxorubicin-induced toxicity, April 2007 Newsletter, p. 8-9

R-CP, Article #6, p. 8

R-CVP

• General information, Article #6,  p.4
• As choice for initial therapy, Article #7, p.14. 
• R-CVP vs. R-CHOP with managerial implications, April 2009 Newsletter, p. 2-5

R-CyP, Article #7, p.13;  February 2008 Newsletter, p. 2-5; August 2007 Newsletter, p. 7-8

R-DHAOx, January 2010 Newsletter, p. 17-19

R-ESHAP, Article #7, p. 15

R-FC, Article #6, p. 6;  Article #7, p.13;  July 2007 Newsletter, p. 10-11

R-FND, Article #6, p. 6;  Article #7, p.13.

R-ICE, Article #6, p. 8

R-PCR (PCR),  January 2009 Newsletter, p. 4-5.

Radiation

• General discussion of research pertaining to the use of low dose field radiation therapy (LDIFRT) in treating fNHL, October 2011 Newsletter, p. 12-13; January 2011 Newsletter, p. 12-14
• Effectiveness of radiation in treating fNHL, September 2010 Newsletter, p. 5-6
• Radiation and early stage lymphoma, June 2009 Newsletter, p. 14-15
• Overview of use in the treatment of fNHL, April 2009 Newsletter,  p. 5-6  
•  Intensity Modulated Radiation Therapy (IMRT), October 2011 Newsletter, p. 12-13; August 2007 Newsletter, p. 10

Rainbow Salad, Article #3, p.38-39

Red Palm Oil, Article #3, p.30; March 2011 Newsletter, p. 12-13; April 2009 Newsletter, p.12-14; June 2007 Newsletter, p.5;  April 2007 Newsletter, p. 9-10

Restless Leg Syndrome, November 2010 Newsletter, p. 15, November 2009 Newsletter, p. 18-19

Resveratrol

• How to calculate the "trans" component in resveratrol supplements and caution re deceptive labeling of resveratrol supplements, November 2011 Newsletter, p. 16-17 
• Resveratrol is on the "A"Team,  Article #3, p. 25-26; March 2010 Newletter, p.16-17
• Suggestions for ingesting resveratrol, April 2011 Newsletter, p. 21-22, December 2010 Newsletter, p. 11
• Research updates on resveratrol, December 2010 Newsletter, p. 10-12
• Resveratrol bioavailability, July 2009 Newsletter, p. 14-15 
• Research on safe dosage, August 2010 Newsletter, p. 17
• Effect on mitochondria, May 2011 Newsletter, p. 13-15, November 2010 Newsletter, p. 10, June 2010 Newsletter, p. 6-7, July 2010 Newsletter, p. 13-15, September 2010 Newsletter, p. 8
• How to read supplement labels to determine the correct dosage for trans-resveratrol, July 2010 Newsletter, p. 14-15
• Resveratrol ability to block cancer cell telomerase, March 2010 Newsletter, p. 6
• Resveratrol, the bcl-6 pathway, and the annoucement of a "new class" of lymphoma drugs in April 2010,  June 2010 Newsletter, p. 6-7
• Summary of research studies on anti-cancer effects of resveratrol, June 2009 Newsletter, p. 11-14
• Research study on resveratrol and transformed fNHL cells, June 2009 Newsletter, p. 11-12
• Precautions on dosing with high-dosage trans-resveratrol, June 2009 Newsletter, p. 13-14

Revlimid/Rituxin Treatment, May 2008 Newsletter, p. 14

Rituximab

• General information, "Rituximab ... Expert Balanced Opinions .. a Must Read", March 2011 Newsletter, p. 9-10;   Article #6,  p. 2-4
• Maintenance rituximab (MR)
• Important Results from RESORT Trial, January 2012 Newsletter, p. 10-13; December 2011, December 2011 Newsletter, p.3-7 
•  "Watch and wait: Maintenance Rituximab ... Latest Expert Opinions", November 2011 Newsletter, p. 2-5
• Summary of research article "The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis", October 2011 Newsletter, p. 10-11 
• "(Maintenance) Rituximab ... Latest Expert Opinions ... a Must Read", June 2011 Newsletter, p. 4-10
• General information on MR, Article #7, p. 11-12; June 2005 Newsletter, p. 3-6
• "Rituximab ... Expert Balanced Opinions ... a Must Read", March 2011 Newsletter, p. 9-10
• "Rituximab Maintenance...Update Commentary", February 2011 Newsletter, p. 7-10
• Risk of infection connected with maitenance rituximab, January 2011 Newsletter, p. 15-17
• August 2010 research update, August 2010 Newsletter, p. 12-13
• Dr. Cheson's critical study on the use of maintenance rituximab, November 2009 Newsletter, p. 9-11 
• Web link to full text of "Hematology: The case against rituximab maintenance", by Dr. Bruce D. Cheson, November 2009 Newsletter, p. 11
• Web link to full text of "What Is the Role of Maintenance Rituximab in Follicular NHL?" by Dr. David Maloney, February 2008 Newsletter, p. 14
• Lifestyle strategies to use during MR, October 2009 Newsletter, p. 19-20
• Duration of MR benefit (chart comparisons), November 2008 Newsletter, p. 14-16; February 2008 Newsletter, p. 12-14 
• Rituximab; Ongoing treatment (maintenance) vs. treatment upon progression, May 2007 Newsletter,  p. 12-14
• Controversial interpretation of "progression free survival" and MR, March 2006 Newsletter, p. 9-12
• Rituximab re-evaluated,  June 2010 Newsletter, p. 9-12
• Rituximab and beta glucans, Article #8, p. 8-9
• Rituximab and exercise, July 2008 Newsletter, p. 11
• Rituximab and colony growth stimulating factors, December 2004 Newsletter, p. 8-9 
• Rituximab and fludarabine (R-FND), Article #7, p. 13
• Rituximab and risk of progressive multifocal leukoencephalopathy (PML),  July 2009 Newsletter, p. 4-8
• "Rituximab, what's known, what isn't",  May 2009 Newsletter, p. 5-7
• Rituximab and immunity, March 2009 Newsletter, p. 15-16
• Rituximab resistance and transformation, February 2010 Newsletter, p. 9-10
• Chlorambucil and rituximab, June 2007 Newsletter, p. 9-10

Root Canals, May 2008 Newsletter, p. 7-8

Rosenberg, Dr. Saul, March 2008 Newsletter, p. 3-6

S

Salmon (Wild), Article #3, p. 39

Salmon Oil (Wild), Article #3, p. 29

Scans

• Radiation dangers, April 2011 Newsletter, p. 7-10, January 2010 Newsletter, p. 14-17
• Radiation exposure of CT scans,  October 2009 Newsletter, p. 13-16;  November 2007 Newsletter, p. 14-16;  January 2006 Newsletter, p. 6-7 
• Recommendations for CT scan frequency,  March 2009 Newsletter, p. 14
• Secondary Cancers, May 2009 Newsletter, p. 12

Selenium

• Selenium as a daily supplement, Article #3, p. 29-30
• Need to be take with Vitamin E, Article #3, p. 29-30;  November 2008 Newsletter, p. 9-10
• Gene P53 and selenium, May 2011 Newsletter, p. 15-16, Article #3, p. 29-30; November 2008 Newsletter, p. 9
• Brazil nuts and selenium supplements -- actual selenium content, November 2008 Newsletter, p.9

Sinus Congestion

• Polysporin and sinus infection, January 2012 Newsletter, p. 23
• Low IgA levels and chronic sinus infection, November 2011 Newsletter, p. 5
• Managing nasal infection and sinus congestion with essential oil vapors, Article #3, p. 52-54
• How to instructions for using steam vapors and essential oils to help clear sinus passages and prevent infection, December 2010 Newsletter, p. 16-18 
• Penetrating nasal passageways with tea tree oil and anise, November 2009 Newsletter,  p.11-14
• Adding oil of oregano to tea tree oil and anise oil mixture, February 2010 Newsletter, p. 16

Skin Conditions, November 2010 Newsletter, p. 15-16

Sleep  

•  Importance of quality sleep, Article #3, p. 19-23; March 2011 Newsletter, p. 21-22 
•  Importance of totally dark room and sleep mask,  Article #3, p. 20;  June 2010 Newsletter, p. 17
• Quality sleep and chronic stress, Article #3, p. 20-23;  February 2005 Newsletter, p. 10-11 
• Sleep and melatonin, Article #3, p. 20-21; September 2006 Newsletter, p. 11-12;  March 2006 Newsletter, p. 9-12
• Quality sleep, nighttime darkness, and breast cancer study, March 2008 Newsletter, p. 15-16
• Sleep and the ROS (reactive oxygen species) cascade, Article #3, p.20-21;  November 2007  Newsletter, p. 9-11;  June 2007 Newsletter, p. 16-17;  December 2006 Newsletter, p. 9-11 
• Sleep and immunity, May 2005 Newsletter, p. 10-12 
• Natural technique for reinforcing the "hormone twins" (Vitamin D and melatonin) for a better night's sleep,  Article #3, p. 20-21;  July 2008 Newsletter, p. 8-10

Spontaneous (Natural) Regression (SR) 

• Medical history of SR and treatment options, Article #7, p. 7-8
• "Must know"  details about SR for follicular patients, October 2009 Newsletter, p. 3-7;  April 2006 Newsletter, p. 9-11
• Spontaneous regression as an indicator of long-term survival, March 2011 Newsletter, p. 20-21;  August 2008 Newsletter, p. 17-18
• Reactive oxygen species (ROS) cascade and spontaneous regression, November 2007 Newsletter, p. 9-11
• Personal reflections on SR, October 2005 Newsletter, p. 2-4

Stages of Follicular Lymphoma,  Article #2, p.4-6

STDs,  December 2009 Newsletter, p. 17-18

Stem Cells (malignant), April 2007 Newsletter, p. 6-8;  December 2006 Newsletter, p. 2-5

Stem Cell Transplants (SCTs)

• New genetic research regarding diffuse components in transformation and relevance to an SCT, November 2011 Newsletter, p. 10-11 
• Autologous SCTs and the presence of the c-Myc gene in pathology reports, October 2011 Newsletter, p. 9-11
• Web link to Greg Dafoe's website Non-Hodgkin's Lymphoma Cyberfamily,for high quality  research and insights on fNHL and SCTs, January 2008 Newsletter, p. 9
• Graft vs. host disease (GVHD) and SCTs, January 2008 Newsletter, p. 10-12 
• Mortality following an autologous SCT, August 2009 Newsletter, p. 11-12
• Relapse after an autologous SCT,  March 2009 Newsletter, p. 14-15
• Mozobil and autologous SCTs, March 2009 Newsletter, p.15; August 2007 Newsletter, p. 6-7
• SCT mortality statistics, January 2009 Newsletter, p. 7-8 
• Autologous SCTs and in-vivo purging, April 2008 Newsletter, p. 8-9
• Autologous SCTs and prognostic indicators for long-term survival, February 2008 Newsletter, p.15
• Second malignancies and SCTs, April 2005 Newsletter, p. 10-12
• Harvesting stem cells, March 2008 Newsletter, p. 8-9
• SCTs and older patients, July 2008 Newsletter, p.  13
• Autologous SCTs and fNHL grade, November 2007 Newsletter, p. 18 
• Studies on long-term effectiveness of autologous SCTs,  August 2007 Newsletter, p. 5-6; October 2006 Newsletter, p.17-20; March 2005 Newsletter, p. 8-11
• Chlorambucil and SCTs, April 2007 Newsletter, p. 6
• Harvesting healthy stems cells, December 2006 Newsletter, p. 5-7
• Allogeneic SCTs, January 2005 Newsletter, p. 6-8

Steroids, January 2009 Newsletter, p. 10-11

Stress

• Article #3, p. 21-23; June 2007 Newsletter, p. 15-16; December 2005 Newsletter, p. 7-8
• Stress and sleep, July 2010 Newsletter, p. 10-13

Sulforaphane

• Sulforaphane in brocolli, brocolli sprouts, and brussels sprouts, a natural histone deacetylase (HDAC) inhibitor, Article #3, 10-12; July 2011 Newsletter, p. 6-10; November 2010 Newsletter, p. 8-9
• Possible benefits of using supplemental sulforaphane in addition to natural sources, Artilce #3, p.38; August 2011 Newsletter, p. 21-22

Sugar

• Sugar as risk factor for cancer, February 2011 Newsletter, p. 17; January 2010 Newsletter, p.19-20 
• Akt cell signaling pathway, sugar, and cancer, June 2008 Newsletter, p. 6-7 
• NF-Kappa B pathway, high sugar intake, and inflammation, February 2008 Newsletter, p.7

Sun exposure (incidence of fNHL), April 2007 Newsletter, p. 3-4

Sunlight

• MIT scientist proposes dietary sulphur intake and sunlight exposure are essential keys to optimal health, November 2011 Newsletter, p. 19-20

Supplement Use

• Discussion of wise and unwise use of supplements and pitfalls of promotional diets, November 2011 Newsletter, p. 5-10
• Dangers of over-using antioxidant supplements, December 2009 Newsletter, p.18-19; November 2009 Newsletter, p.15-16;  July 2009 Newsletter, p.12-14;  May 2008 Newsletter, p.12-13
• Norwegian clinical trial investigates effect of supplementation with omega 3 fatty acids (fish oil), selenium, garlic, ellagic acid (pomegranate juice), resveratrol/quercetin (grape juice/red wine and EPCG (green tea) on fNHL, June 2007 Newsletter, p. 16

Survival (see Long-Term Survival)

________________________________

T

T-Cell Immunotherapy, June 2005 Newsletter, p. 1-3

Targeted Natural Strategies (TNS) for Long-Term Survival  (see also Lifestyle Strategies)

• "Living the Natural Strategies Everyday", August 2011 Newsletter, p. 3-11 
• Scientific premises for TNS, Article #3, p. 4-5
• Updated dietary and supplementation strategies, Article #3, p. 23-46; October 2010 Newsletter, p. 8-19 
• Importance of Targeted Natural Strategies, Article #2, p.22-25; March 2007 Newsletter, p. 4-11 
• Essence of Targeted Natural Strategies (the A Team), March 2008 Newsletter, p. 6-8
• Controversy concerning  the use of TNS and fNHL, October 2006, p. 3-8
• Importance of the "before and after" strategy, September 2010 Newsletter, p. 7-9

Telomerase

• Telomerase, telomeres, and cancer cells, June 2007 Newsletter, p. 8-9
• Telomerase key to developing potential cancer breakthrough, March 2010 Newsletter, p.6

Tempo, Article #7, p. 7

Toxoplasmosis, July 2006 Newsletter, p. 7-8

Transformation 

• Interpretation of diffuse pattern results in tissue biopsies as it pertains to diagnosing transformation,  September 2011 Newsletter, p. 17-18 
• Chemotherapy and transformation, September 2010 Newsletter, p. 3-6 
• Understanding transformation, Article #2, p. 25-27;  Article #4 p. 1-2;  Article #7, p. 4-5;  November 2009 Newsletter, p. 5-9;  February 2006 Newsletter, p. 2-9 
• Rosenberg, Dr. Saul, "Follicular Lymphoma Re-Visited", March 2008 Newsletter, p. 3-6
• Planning for transformation: most important considerations, Article #7, p.16
• Critical information on possible shortage of chemotherapy drugs used to treat transformation, December 2010 Newsletter, p. 15-16
• Major treatment implications of transformation, Article #4, p. 2-9
• Elevated LDH and transformation, Article #4, p. 2
• Role of gene P53 in transformation, Article #4, p. 5; January 2008 Newsletter, p. 13-14
• Risk of transformation rises 3% per year, November 2008 Newsletter, p.10-11 
• Natural strategies to combat transformation, November 2008 Newsletter, p. 12-13 
• Resveratrol and transformation, Article #4,  p. 5-6
• R-CHOP and transformation, Article #4, p.2-4, and p.6
• Web link to Dr. Zelenetz webcast on transformation, January 2011 Newsletter, p. 20 
• PET scans and transformation, Article #4, p.9 
• Have I transformed?, July 2007 Newsletter, p. 11-14
• "Transformation: A Yes or No Event?", March 2010 Newsletter, p. 9-11 
• B Symptoms and transformation, Article #3, p. 60-61
• Treatments for second transformation,  Article #7,  p.15
• Biomarkers, predicting overall survival time,and transformation, September 2008 Newsletter, p. 5-6
• Rituximab resistance and transformation, February 2010 Newsletter, p. 9-10
• Research study on resveratrol and transformed fNHL cells, June 2009 Newsletter, p. 11-12 
• Risk factors for transformation, November 2006 Newsletter, p. 9-12

Treatment-Wellness Spectrum, Article #3, p. 12, April 2011 Newsletter, p. 3-4, March 2010 Newsletter, p. 15-16: August 2008 Newsletter, p. 3-5;  February 2010 Newsletter, p. 17

Triphala, June 2008 Newsletter, p.10

__________________________________________________________

U

_____________________________________________________________

V

Vaccines

• Biovest vaccine,  August 2009 Newsletter, p.12-13;  July 2008 Newsletter, p.14-17;  January 2008 Newsletter, p. 5-6;  December 2007 Newsletter, p.15-16 
• Vaccine novelty, July 2008 Newsletter, p.14-17
• Why cancer vaccines may not work, June 2009 Newsletter, p.17-18;  February 2009 Newsletter, p.12;  January 2008 Newsletter, p.4-5;  May 2005 Newsletter, p. 4-7
• Bendandi vaccine, September 2008 Newsletter, p.16;  March 2008 Newsletter, p. 9-10;  January 2008 Newsletter, p.6;  May 2007 Newsletter, p.2;  January 2007 Newsletter, p. 2-5 
• Favrille vaccine, June 2008 Newsletter, p.11-12; January 2008 Newsletter, p.5 ; December 2007 Newsletter, p.15 
• MyVax vaccine,  January 2008 Newsletter, p.2-4;  December 2007 Newsletter, p.14-15
• Common terminology used in discussing vaccine therapy, May 2005 Newsletter, p 6-7

Vascularization

• Vascularization and fNHL,  December 2007 Newsletter, p. 8-9
• Research identifying vascularization as a strong prognostic indicator in regard to transformation and overall survival in fNHL, September 2010 Newsletter, p. 13-14
• Ellagic acid and vascularization, September 2010 Newsletter, p. 14

Vegetable intake and lymphoma, July 2006 Newsletter, p. 6-7

Vitamin B-12, Article #3, p. 32; July 2009 Newsletter, p. 15-16

Vitamin D 

• "The Sensible Management of Vitamin D", November 2011 Newsletter, p. 13-16 
• Ensuring a year-round optimum level of Vitamin D,  Article #3, p. 14-19
• Vitamin D testing information, April 2011 Newsletter, p. 21
• Clinical research studies on cancer and Vitamin D levels
• Cancer patients have lower vitamin D levels, January 2012 Newsletter, p. 10-13
• Clinical trial results show insufficient Vitamin D levels in CLL patients linked to cancer progression and survival times, December 2010 Newsletter, p. 9
• December 2009 Newsletter, p.13-15
• New model of cancer development cites low Vitamin D, June 2009 Newsletter, p. 9-10
• Vitamin D and depression, October 2008 Newsletter, p.12
• Breast cancer and low levels of Vitamin D, June 2008 Newsletter, p. 5-6 
• Mayo Clinic 2010 research on Vitamin D and fNHL, September 2010 Newsletter, p. 14-16
• Vitamin D supplements and dosage considerations, October 2009 Newsletter, p. 7-9
• Barriers in achieving optimal Vitamin D levels, June 2009 Newsletter, p. 4-9;  May 2008 Newsletter, p. 6-9 
• Fat solubility and supplementation,  Article #3, p. 15
• "Vitamin D and Immunity: A Double-Edged Sword", May 2010 Newsletter, p. 7-9
• Vitamin A may limit optimization of Vitamin D, March 2010 Newsletter, p. 14-15
• Vitamin D and sunlamps,  Article #3, p.18-19
• Vitamin D and sunscreen, June 2010 Newsletter, p. 18
• Vitamin D and bathing,  February 2010 Newsletter, p. 14 
• Personal comments from Dr. Gabe Mirkin,  May 2009 Newsletter, p. 13-14;  May 2008 Newsletter, p. 2-6, September 2010 Newsletter, p. 16 

Vitamin E 

• "Vital Role of Full Spectrum Vitamin E", March 2011 Newsletter, p. 12-13 
• Vitamin E tocotrienols anti-cancer benefits, April 2009 Newsletter, p. 12-14 
• Almonds and almond milk as a source of Vitamin E, Article #3, p.27 
• Rice bran oil as source of tocotrienol component of Vitamin E, March 2011 Newsletter, p. 12-13
• Red palm oil as a full-spectrum source of Vitamin E, May 2011 Newsletter, p. 15-16, March 2011 Newsletter, p. 12-13;  Article #3, p. 30;  April 2009 Newsletter, p. 12-14
• Vitamin E needs to be taken with selenium,  Article #3, p. 27-28
• Vitamin E and NF-Kappa B pathway,  January 2008 Newsletter, p. 17-18

Vitamin K

• The importance of K-2 (menaquinone) and how to get it from dietary sources, Article #3, p. 40-41; November 2011 Newsletter, p. 20; September 2011 Newsletter, p. 18-19 
• Green leafy vegetables as source of vitamin K-1,  Article #3, p. 40-41
• Mayo Clinic research study, April 2010, May 2010 Newsletter, p. 13-14

W

Walnuts,  Article #3, p. 26-27; April 2011 Newsletter, p. 23

Warburg, Dr. Otto

• Dr. Warburg's contributions to understanding cancer causation, June 2010 Newsletter, p. 3-6
• Dr. Warburg's theory about cancer and lack of effective mitochondrial function in cancer cells, November 2010 Newsletter, p.10

Watch and wait (see Dynamic Observation)

Weil, Dr. Andrew, March 2008 Newsletter, p. 17-18, May 2010 Newsletter, p. 17 

Y

Z

Zevalin

• General information, Article #6,  p.7 
• Zevalin manufacturer requests removal of pre-treatment evaluation bioscan, February 2011 Newsletter, p. 13-14
• Significance of FDA approval, September 2009 Newsletter, p. 2-6
• Research comparing Zevalin and Bexxar,  July 2008 Newsletter, p. 13-14
• 2008 Italian research study,  April 2008 Newsletter, p. 7-8
• Reseach evaluating effectiveness, June 2010 Newsletter, p.12-13

Zinc, Article #3, p.29